Why is the New York Times Writing so Much about Alzheimer's Disease Therapies?

by Tamas Bartfai
Published 2010-01-01

Fever

by Tamas Bartfai, Bruno Conti
Published 2010-01-01

Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle

by Tamas Bartfai, Graham V. Lees
Published 2020-04-01

Pharma TARP: A Troubled Asset Relief Program for Novel, Abandoned Projects in the Pharmaceutical Industry

by Tamas Bartfai, Graham Vaughan Lees
Published 2011-01-01

Midlife interventions are critical in prevention, delay, or improvement of Alzheimer’s disease and vascular cognitive impairment and dementia [version 1; referees: 2 approved]

by Sam Gandy, Tamas Bartfai, Graham V. Lees, Mary Sano
Published 2017-04-01

Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.

by Min He, Haoran Su, Weiwei Gao, Stina M Johansson, Qing Liu, Xiaoyan Wu, Jiayu Liao, Andrew A Young, Tamas Bartfai, Ming-Wei Wang
Published 2010-01-01

Primary Cell Culture of Live Neurosurgically Resected Aged Adult Human Brain Cells and Single Cell Transcriptomics

by Jennifer M. Spaethling, Young-Ji Na, Jaehee Lee, Alexandra V. Ulyanova, Gordon H. Baltuch, Thomas J. Bell, Steven Brem, H. Isaac Chen, Hannah Dueck, Stephen A. Fisher, Marcela P. Garcia, Mugdha Khaladkar, David K. Kung, Timothy H. Lucas Jr., Donald M. O’Rourke, Derek Stefanik, Jinhui Wang, John A. Wolf, Tamas Bartfai, M. Sean Grady, Jai-Yoon Sul, Junhyong Kim, James H. Eberwine
Published 2017-01-01